Edwards Lifesciences Corp (NYSE:EW) CEO Michael A. Mussallem sold 32,800 shares of the stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $126.69, for a total value of $4,155,432.00. Following the completion of the transaction, the chief executive officer now directly owns 74,131 shares in the company, valued at approximately $9,391,656.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Michael A. Mussallem also recently made the following trade(s):

  • On Thursday, January 4th, Michael A. Mussallem sold 32,800 shares of Edwards Lifesciences stock. The shares were sold at an average price of $114.97, for a total value of $3,771,016.00.
  • On Tuesday, December 19th, Michael A. Mussallem sold 32,800 shares of Edwards Lifesciences stock. The shares were sold at an average price of $114.82, for a total value of $3,766,096.00.
  • On Monday, November 20th, Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences stock. The shares were sold at an average price of $106.86, for a total value of $3,515,694.00.

Shares of Edwards Lifesciences Corp (NYSE EW) opened at $127.35 on Wednesday. Edwards Lifesciences Corp has a 12 month low of $89.20 and a 12 month high of $138.48. The firm has a market cap of $26,852.45, a PE ratio of 33.39, a PEG ratio of 1.87 and a beta of 0.63. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.15.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, February 1st. The medical research company reported $0.94 EPS for the quarter, beating the Zacks’ consensus estimate of $0.91 by $0.03. The firm had revenue of $888.50 million during the quarter, compared to the consensus estimate of $868.45 million. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.69%. The firm’s revenue was up 15.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.75 earnings per share. research analysts expect that Edwards Lifesciences Corp will post 4.49 EPS for the current fiscal year.

Edwards Lifesciences announced that its Board of Directors has approved a share buyback plan on Thursday, December 7th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the medical research company to reacquire shares of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.

A number of large investors have recently made changes to their positions in the stock. Avalon Global Asset Management LLC acquired a new stake in Edwards Lifesciences in the fourth quarter valued at about $2,254,000. Sectoral Asset Management Inc lifted its position in Edwards Lifesciences by 19.2% in the fourth quarter. Sectoral Asset Management Inc now owns 158,100 shares of the medical research company’s stock valued at $17,819,000 after purchasing an additional 25,520 shares during the period. Amundi Pioneer Asset Management Inc. lifted its position in Edwards Lifesciences by 61.6% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 1,115,658 shares of the medical research company’s stock valued at $125,747,000 after purchasing an additional 425,186 shares during the period. Alliancebernstein L.P. lifted its position in Edwards Lifesciences by 12.1% in the fourth quarter. Alliancebernstein L.P. now owns 6,259,771 shares of the medical research company’s stock valued at $705,539,000 after purchasing an additional 675,216 shares during the period. Finally, Unio Capital LLC acquired a new stake in Edwards Lifesciences in the fourth quarter valued at about $225,000. Hedge funds and other institutional investors own 81.11% of the company’s stock.

Several research firms recently commented on EW. Cowen reissued a “buy” rating and issued a $150.00 target price on shares of Edwards Lifesciences in a report on Thursday, February 1st. Zacks Investment Research raised Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $145.00 target price on the stock in a report on Thursday, February 8th. Stifel Nicolaus reissued a “buy” rating and issued a $155.00 target price on shares of Edwards Lifesciences in a report on Friday, February 2nd. SunTrust Banks reissued a “buy” rating and issued a $150.00 target price on shares of Edwards Lifesciences in a report on Wednesday, January 31st. Finally, JMP Securities increased their target price on Edwards Lifesciences from $135.00 to $140.00 and gave the company a “market outperform” rating in a report on Friday, February 2nd. Three analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $141.15.

COPYRIGHT VIOLATION NOTICE: “Edwards Lifesciences Corp (EW) CEO Sells $4,155,432.00 in Stock” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://theolympiareport.com/2018/02/14/edwards-lifesciences-corp-ew-ceo-sells-4155432-00-in-stock.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.